Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • larrystone13 larrystone13 Mar 1, 2013 7:33 PM Flag

    Motley Fool " I DON'T EXCEPT A CO. TO GIVE GUIDANCE AFTER ONE MONTHS OF SALES. ( link )

    Motley Fool
    By Brian Orelli | More Articles | Save For Later
    March 1, 2013

    Unfortunately, management was light on the details last night beyond qualitative comments such as CEO Joseph Zakrzewski saying, "we're pleased to-date with the progress that our sales representatives are making out in the field."

    I don't expect a company to give full-year guidance after a drug has been on the market for a month. If management did give guidance, it would likely be completely useless since any smart management team would be insanely conservative with their guidance. Regeneron Pharmaceuticals (NASDAQ: REGN ) raised guidance for its macular degeneration drug, Eylea, four times last year. That's not guidance; that's guesses. And bad ones at that. Eylea sales were five times higher than initial estimates.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AMRN
2.31-0.01(-0.43%)May 29 4:00 PMEDT